Amphotericin B by Cystetic Medicines for Cystic Fibrosis: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Amphotericin B overview

Amphotericin B (CM-001) is under development for the treatment of cystic fibrosis. The drug candidate is administered through inhalation as a dry powder. It acts by targeting cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Cystetic Medicines overview

Cystetic Medicines is a developer of cystic fibrosis drug which focuses to provide a new way to treat the disease in patients and to improve lung function. The company is headquartered in Champaign, Illinois, the US.

For a complete picture of Amphotericin B’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.